Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Industries

    HPV vaccine makers eye growth overseas

    Companies make notable inroads abroad amid near market saturation in domestic sector

    By LI JIAYING and LIU ZHIHUA | China Daily | Updated: 2024-11-28 10:19
    Share
    Share - WeChat
    A view of bivalent HPV vaccine of Wantai Biopharm in Chongqing on Nov 8. SUN KAIFANG/FOR CHINA DAILY

    In August, Shandong province's online procurement platform revealed that Walvax's bivalent HPV vaccine was priced at just 27.5 yuan per dose — about the same price as a cup of coffee.

    "Eyeing a higher public health level, a lot of local governments have beefed up efforts to provide free bivalent HPV vaccines for females under 15 through government procurement. And reasonable price reductions happening in this progress are a good thing, as they enhance vaccine accessibility, accelerate domestic substitution and promote a higher vaccination rate, benefiting the industry's healthy development," said Tao Ran, CEO of Beijing Health Guard Biotechnology Inc, an innovative vaccine producer.

    According to the National Health Commission, as of mid-October, the free HPV vaccination policy had covered about 40 percent of women of eligible age nationwide.

    Tao suggested that as competition intensifies in the lower-valent vaccine market, breakthroughs may lie in the higher-valent vaccine segment and the development of vaccines for male indications.

    Health Guard's nine-valent HPV vaccine, covering both male and female indicators, is currently in phase-III clinical trials. Nine-valent products of other players, such as Jiangsu Recbio Technology Co Ltd and Shanghai-based Bovax Biotechnology, are also in advanced clinical stages. Notably, Wantai's application for market entry of its nine-valent HPV vaccine was accepted in August, marking the first such domestic application.

    "Lower and higher-valent vaccines may complement each other in meeting different market needs," Tao said, adding that the former, being cost-effective, meet basic prevention needs, while the latter provide more comprehensive protection and may be chosen by more and more consumers as life quality has been largely improved during recent years.

    Tao also said with the sequential approval of domestic nine-valent vaccines, competition is expected to gradually extend from the female market to the male market and eventually boost overall immunization levels worldwide.

    "China's HPV market still holds tremendous potential. To date, only five HPV vaccines for females have been approved in the country, without anything of the same category for males," he said.

    Data from consultancy Frost & Sullivan showed that in 2020, the number of males in China eligible for HPV vaccination (aged 9 to 45) reached 344 million, requiring about 980 million doses for full vaccination coverage. To date, there are merely three HPV vaccines designed for male use that have entered phase-III clinical trials in China.

    "Many women are already well-informed about cervical cancer and HPV vaccines. With the expansion of indicators to include males in the future, more people are expected to gain awareness of this topic, which will further aid in educating the public about cervical cancer prevention and eradication efforts," said Sun Xiaodong, deputy director of the Shanghai Municipal Center for Disease Control and Prevention.

    For many Chinese vaccine manufacturers, tapping the expanding overseas markets has also become a key step to counter fierce domestic competition and achieve broader growth.

    For example, Health Guard said it is conducting phase-III trials for its nine-valent HPV vaccine in Indonesia and plans to submit a market application to relevant departments by 2025. The company also seeks broader market expansion in other ASEAN countries, it said.

    Wantai's bivalent HPV vaccine has also gained market access in 18 countries, primarily in Asia and Africa, with registration applications underway in 10 additional countries across Asia, Africa and Latin America, the company said.

    In addition, Recbio announced earlier this year a comprehensive strategic partnership with Saudi pharmaceutical company Spimaco, authorizing it to develop, register, and commercialize a nine-valent HPV vaccine in 15 countries in the Middle East and North Africa.

    "There is still significant demand in many developing countries, offering new opportunities for Chinese manufacturers," said Yang Huaiyu, a consumer industry analyst.

    "Southeast Asia, with its large population and low vaccination coverage, presents a promising direction for exports and a vast potential market," said Liu Lihe, executive director at China Insights Consultancy.

    However, the diverse income levels and healthcare systems in Southeast Asian countries mean Chinese manufacturers must adopt tailored sales and consumer education strategies, while also engaging extensively with local public health systems, Liu said.

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    国产精品va无码一区二区 | 久久久久亚洲AV无码专区桃色 | 日本精品自产拍在线观看中文| 国内精品人妻无码久久久影院| 亚洲欧美成人久久综合中文网| 日本中文字幕在线| 久久久久亚洲?V成人无码| 久久久久久久人妻无码中文字幕爆| 中文字幕无码不卡在线| 狠狠干中文字幕| 中文亚洲欧美日韩无线码| 国产亚洲?V无码?V男人的天堂 | 久久精品aⅴ无码中文字字幕重口| 无码国产精品一区二区免费式直播 | 日本中文字幕在线视频一区| 中文字幕日本人妻久久久免费| 无码精品一区二区三区免费视频| 亚洲人成人无码网www电影首页| 十八禁视频在线观看免费无码无遮挡骂过 | 无码国产精品一区二区免费16 | 狠狠噜天天噜日日噜无码| 少妇无码AV无码专区在线观看| 亚洲人成无码网站| 中文人妻无码一区二区三区| 日日摸夜夜爽无码毛片精选| 中文字幕日韩精品有码视频 | 亚洲热妇无码AV在线播放| 成在人线av无码免费高潮喷水| 欧美日韩毛片熟妇有码无码| 最近最新中文字幕视频| 无码福利一区二区三区| 国产成人精品一区二区三区无码| 国产网红主播无码精品| 国产aⅴ无码专区亚洲av麻豆| 中文字幕无码日韩专区| 亚洲国产综合无码一区| 免费A级毛片无码A∨| 在线看无码的免费网站| 亚洲精品一级无码鲁丝片| 日韩一本之道一区中文字幕| 色婷婷久久综合中文久久蜜桃av|